6-[4-(5-ethyl-2H-pyrazol-3-ylamino)-quinazolin-2-ylamino]-1,2-dihydro-indazol-3-one | 685866-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-[4-(5-ethyl-2H-pyrazol-3-ylamino)-quinazolin-2-ylamino]-1,2-dihydro-indazol-3-one
• 英文别名: 6-[[4-[(5-ethyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]amino]-1,2-dihydroindazol-3-one
• CAS: 685866-73-3
• 化学式: C₂₀H₁₈N₈O
• 分子量: 386.416
• InChiKey: FKOMHJQZPROKGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  120
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Indazolinone compositions useful as kinase inhibitors
  申请人：——

  公开号：US20040167121A1

  公开（公告）日：2004-08-26

  The present invention provides compounds of formula I: 1 These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

  本发明提供了I式化合物：1这些化合物及其药学上可接受的组合物通常用作激酶抑制剂，特别是作为PRAK、GSK3、ERK2、CDK2、MK2、SRC、SYK和AuroRA-2的抑制剂。因此，本发明的化合物和组合物可用于治疗或减轻各种疾病的严重程度，包括但不限于心脏病、糖尿病、阿尔茨海默病、免疫缺陷病、炎症性疾病、过敏性疾病、自身免疫疾病、破坏性骨疾病如骨质疏松症、增生性疾病、传染病和病毒性疾病。
• INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS
  申请人：Aronov Alex

  公开号：US20090048250A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

  本发明提供了I式化合物：这些化合物及其药学上可接受的组合物通常用作激酶抑制剂，特别是作为PRAK、GSK3、ERK2、CDK2、MK2、SRC、SYK和AuroRA-2的抑制剂。因此，本发明的化合物和组合物可用于治疗或减轻各种疾病的严重程度，包括但不限于心脏疾病、糖尿病、阿尔茨海默病、免疫缺陷病、炎症性疾病、过敏性疾病、自身免疫性疾病、破坏性骨疾病（如骨质疏松症）、增生性疾病、传染病和病毒性疾病。
• US7262200B2
  申请人：——

  公开号：US7262200B2

  公开（公告）日：2007-08-28
• US7842712B2
  申请人：——

  公开号：US7842712B2

  公开（公告）日：2010-11-30